Skip to main content
. Author manuscript; available in PMC: 2019 May 21.
Published in final edited form as: Med Care. 2017 Jul;55(7):669–676. doi: 10.1097/MLR.0000000000000727

Table 2.

Measures of Treatment Duration and Continuity for Individuals Receiving First Episodes of Buprenorphine-Naloxone Treatment

Outcome Value
Retained for ≥180 days 41.4%
Mean episode 1 length 266 days
Median episode 1 length 118 days
Mean Daily Dosage 14.1 mg/day
Low possession ratio (<.80) among individuals with ≥3 fills 30.2%
At least 1 interruption of >14 days among individuals with ≥3 fills 25.5%

NOTES: Authors’ analysis of individuals initiating first episode of buprenorphine-naloxone treatment in the IMS LifeLink database in 2010–2012. The total sample of individuals=27,273, the sample of individuals with ≥3 fills=18,654.